{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:02:35Z","timestamp":1784682155699,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":446,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.cmi.2022.08.024","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:35:06Z","timestamp":1662438906000},"page":"150-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Short-course antibiotics for common infections: what do we know and where do we go from here?"],"prefix":"10.1016","volume":"29","author":[{"given":"Rachael A.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Stripling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Spellberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Centor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.08.024_bib1","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2105\/AJPH.2007.124446","article-title":"Alternatives to the randomized controlled trial","volume":"98","author":"West","year":"2008","journal-title":"Am J Public Health"},{"key":"10.1016\/j.cmi.2022.08.024_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/526535","article-title":"The Maxwell Finland lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile","volume":"46","author":"Rice","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib3","article-title":"The shorter is better movement: past, present, future","author":"Spellberg","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.08.024_bib4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.7326\/M20-7355","article-title":"Appropriate use of short-course antibiotics in common infections: best practice advice from the American College of Physicians","volume":"174","author":"Lee","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2022.08.024_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00635-18","article-title":"Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults","volume":"62","author":"Tansarli","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.08.024_bib6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(21)00313-5","article-title":"Discontinuing \u03b2-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial","volume":"397","author":"Dinh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.08.024_bib7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1001\/jama.2021.17843","article-title":"Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT randomized clinical trial","volume":"326","author":"Bielicki","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.08.024_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamapediatrics.2021.5547","article-title":"Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial","volume":"176","author":"Williams","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.cmi.2022.08.024_bib9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/INF.0000000000003558","article-title":"Extended versus standard antibiotic course duration in children <5 years of age hospitalized with community-acquired pneumonia in high-risk settings: four-week outcomes of a multicenter, double-blind, parallel, superiority randomized controlled trial","volume":"41","author":"McCallum","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2022.08.024_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1912400","article-title":"Amoxicillin for 3 or 5 days for chest-indrawing pneumonia in Malawian children","volume":"383","author":"Ginsburg","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.08.024_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamapediatrics.2020.6735","article-title":"Short-course antimicrobial therapy for pediatric community-acquired pneumonia: the SAFER randomized clinical trial","volume":"175","author":"Pernica","year":"2021","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.cmi.2022.08.024_bib12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cmi.2022.08.024_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diagmicrobio.2013.11.008","article-title":"A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia","volume":"80","author":"Zhao","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0140-6736(02)09994-4","article-title":"Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.08.024_bib15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/INF.0000000000000023","article-title":"Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial","volume":"33","author":"Greenberg","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2022.08.024_bib16","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","volume":"332","author":"el Moussaoui","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.08.024_bib17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2022.08.024_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00006454-199810000-00004","article-title":"Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children","volume":"17","author":"Harris","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2022.08.024_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02561528","article-title":"Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study","volume":"27","author":"Sch\u00f6nwald","year":"1999","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2022.08.024_bib20","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.08.024_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041290","article-title":"Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment","volume":"7","author":"Capellier","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2022.08.024_bib22","first-page":"CD007577","article-title":"Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults","volume":"10","author":"Pugh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2022.08.024_bib23","first-page":"CD007577","article-title":"Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults","volume":"2015","author":"Pugh","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2022.08.024_bib24","series-title":"Complicated urinary tract infections: developing drugs for treatment guidance for industry","year":"2018"},{"key":"10.1016\/j.cmi.2022.08.024_bib25","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practise guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1988.tb15899.x","article-title":"One or three weeks\u2019 treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam","volume":"223","author":"Jernelius","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.cmi.2022.08.024_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0924-8579(95)00011-V","article-title":"A sequential study of intravenous and oral fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections","volume":"6","author":"de Gier","year":"1995","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2022.08.024_bib28","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.08.024_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"Sandberg","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.08.024_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.cmi.2022.08.024_bib31","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10096-017-2951-6","article-title":"Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial","volume":"36","author":"Dinh","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","article-title":"Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women","volume":"15","author":"van Nieuwkoop","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2022.08.024_bib33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.2021.9899","article-title":"Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial","volume":"326","author":"Drekonja","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.08.024_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/sur.2009.9930","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America","volume":"11","author":"Solomkin","year":"2010","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.cmi.2022.08.024_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/sur.2012.077","article-title":"Association of excessive duration of antibiotic therapy for intra-abdominal infection with subsequent extra-abdominal infection and death: a study of 2,552 consecutive infections","volume":"15","author":"Riccio","year":"2014","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.cmi.2022.08.024_bib36","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1469-0691.2006.01507.x","article-title":"Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy","volume":"12","author":"Seguin","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.08.024_bib37","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib38","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.08.024_bib39","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","article-title":"Trial of short-course antimicrobial therapy for intraabdominal infection","volume":"372","author":"Sawyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.08.024_bib40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00134-018-5088-x","article-title":"Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial","volume":"44","author":"Montravers","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2022.08.024_bib41","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0924-8579(09)70567-9","article-title":"Short-course therapy for bloodstream infections in immunocompetent adults","volume":"34","author":"Corey","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2022.08.024_bib42","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteraemia: a noninferiority randomized controlled trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib43","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteraemia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.08.024_bib44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial","volume":"28","author":"Molina","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.08.024_bib45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib46","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib47","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/archinte.164.15.1669","article-title":"Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis","volume":"164","author":"Hepburn","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2022.08.024_bib48","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.08.024_bib49","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib50","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cmi.2019.09.019","article-title":"Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomized, double-blind, placebo-controlled, non-inferiority trial","volume":"26","author":"Cranendonk","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.08.024_bib51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/SLA.0000000000005205","article-title":"Moderate to severe soft tissue diabetic foot infections: a randomized, controlled, pilot trial of post-debridement antibiotic treatment for 10 versus 20 days","volume":"276","author":"Truong-Thanh","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.cmi.2022.08.024_bib52","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious Diseases Society of America clinical practise guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib53","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2337\/dc14-1514","article-title":"Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study","volume":"38","author":"Tone","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2022.08.024_bib54","doi-asserted-by":"crossref","first-page":"e1539","DOI":"10.1093\/cid\/ciaa1758","article-title":"Three weeks versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, noninferiority pilot trial","volume":"73","author":"Gariani","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc13-1526","article-title":"Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial","volume":"37","author":"L\u00e1zaro-Mart\u00ednez","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmi.2022.08.024_bib56","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","article-title":"Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial","volume":"385","author":"Bernard","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.08.024_bib57","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/jac\/dkz202","article-title":"Four versus six weeks of antibiotic therapy for osteoarticular infections after implant removal: a randomized trial","volume":"74","author":"Benkabouche","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.08.024_bib58","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2019-215116","article-title":"Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial","volume":"78","author":"Gjika","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib59","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijantimicag.2016.05.021","article-title":"Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial","volume":"48","author":"Lora-Tamayo","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2022.08.024_bib60","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa2020198","article-title":"Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection","volume":"384","author":"Bernard","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.08.024_bib61","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11321","article-title":"Use of novel strategies to develop guidelines for management of pyogenic osteomyelitis in adults: a WikiGuidelines Group Consensus Statement","volume":"5","author":"Spellberg","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2022.08.024_bib62","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/antibiotics9110733","article-title":"Short- vs. long-course antibiotic treatment for acute streptococcal pharyngitis: systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Holm","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2022.08.024_bib63","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0009922811409571","article-title":"Adolescent pharyngitis: a review of bacterial causes","volume":"50","author":"Mitchell","year":"2011","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.cmi.2022.08.024_bib64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1473-3099(19)30039-8","article-title":"Macrolide resistance in Streptococcus spp","volume":"19","author":"Tsuzuki","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.08.024_bib65","doi-asserted-by":"crossref","first-page":"l5337","DOI":"10.1136\/bmj.l5337","article-title":"Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open label, non-inferiority study","volume":"367","author":"Skoog St\u00e5hlgren","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.08.024_bib66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2125.2008.03306.x","article-title":"Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials","volume":"67","author":"Falagas","year":"2009","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200461X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200461X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:32:51Z","timestamp":1761118371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2200461X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1198743X2200461X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.08.024","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-course antibiotics for common infections: what do we know and where do we go from here?","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}